Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Microbiology and Infection

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1469-0691.2010.03335.xPMID 20678176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.

  2010cited by this paper
• Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.

  2010cited by this paper
• Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials

  2010cited by this paper
• Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

  2010cited by this paper
• Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

  2009cited by this paper
• In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine

  2008cited by this paper
• Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs.

  2008cited by this paper
• Perspectives and opportunities for novel antiviral treatments targeting virus fitness.

  2008cited by this paper
• HIV‐1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy

  2008cited by this paper
• Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors

  2007cited by this paper
• Chemokine antagonists as therapeutics: focus on HIV-1.

  2007influential reference
• Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)

  2006cited by this paper
• Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART

  2006cited by this paper
• KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.

  2005cited by this paper
• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

  2005cited by this paper
• Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation

  2005cited by this paper
• Genotypic and Phenotypic Correlates of the HIV Type 1 env Gene Evolution in Infected Children with Discordant Response to Antiretroviral Therapy

  2004cited by this paper
• Memory in Retroviral Quasispecies: Experimental Evidence and Theoretical Model for Human Immunodeficiency Virus

  2003cited by this paper
• The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

  2003cited by this paper
• Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors

  2003cited by this paper
• Diminished RNA Primer Usage Associated with the L74V and M184V Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Provides a Possible Mechanism for Diminished Viral Replication Capacity

  2003cited by this paper
• Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

  2003cited by this paper
• Resistance of virus to extinction on bottleneck passages: Study of a decaying and fluctuating pattern of fitness loss

  2003cited by this paper
• Duration and fitness dependence of quasispecies memory.

  2002cited by this paper
• Error catastrophe and antiviral strategy

  2002cited by this paper
• Fitness of drug resistant HIV-1: methodology and clinical implications.

  2002cited by this paper
• Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

  2001cited by this paper
• Structured treatment interruptions in antiretroviral management of HIV-1

  2001cited by this paper
• Implications of antiretroviral resistance on viral fitness

  2001cited by this paper
• The evolution of HIV

  2001cited by this paper
• HIV drug resistance and viral fitness.

  2000cited by this paper
• Memory in Viral Quasispecies

  2000cited by this paper
• Mutation rates among RNA viruses.

  1999cited by this paper
• Universal DNA microarray method for multiplex detection of low abundance point mutations.

  1999cited by this paper
• RNA virus mutations and fitness for survival.

  1997cited by this paper
• Molecular Basis of Virus Evolution: Quasi-species: the concept and the word

  1995cited by this paper
• Infection of the SCID-hu mouse by HIV-1.

  1988cited by this paper

• Evolution Driven By A Varying Host Environment Selects For Distinct HIV-1 Entry Phenotypes and Other Informative Variants.

  2023cites this paper
• Viral Fitness, Population Complexity, Host Interactions, and Resistance to Antiviral Agents.

  2023cites this paper
• Heterosubtypic immune pressure accelerates emergence of influenza A virus escape phenotypes in mice

  2022cites this paper
• Viral fitness as a measure of adaptation

  2020cites this paper
• Quasispecies dynamics in disease prevention and control

  2019cites this paper
• Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil

  2016cites this paper
• Correction: Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil

  2016cites this paper
• Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.

  2015cites this paper
• Viral Fitness in Hosts

  2015cites this paper
• Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms

  2015cites this paper
• Quasispecies Dynamics in Disease Prevention and Control

  2015influential citation
• HIV‐1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy

  2015cites this paper
• Mutacije povezane s rezistencijom virusa ljudske imunodeficijencije tipa 1 na antiretrovirusne lijekove

  2014cites this paper
• Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

  2013cites this paper
• Possible HIV transmission modes among at‐risk groups at an early epidemic stage in the Philippines

  2013cites this paper
• Nanotecnología y microbicidas: protección frente a la infección por VIH

  2012cites this paper
• Viral fitness: definitions, measurement, and current insights

  2012cites this paper
• Viral Quasispecies Evolution

  2012cites this paper
• Chemokine receptor CCR5: from AIDS to atherosclerosis

  2011cites this paper